GlassScriptPhysician profile
Jeffrey Lyle Summe
NPI 1861409732
$14,339.34
in general payments reported to CMS, 2019-2025
41 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,512 · 2020: $2,892 · 2021: $2,760 · 2022: $2,063 · 2023: $1,201 · 2024: $511 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,013.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Orexo US, INC. | $1,705.02 | 2019-2025 | Zubsolv |
| Novo Nordisk INC | $1,258.86 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,234.40 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Gilead Sciences, INC. | $1,168.70 | 2019-2022 | |
| Abbvie INC. | $909.74 | 2021-2025 | Mavyret, Ubrelvy, Qulipta |
| Zyla Life Sciences, INC. | $772.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $724.64 | 2019-2022 | |
| Pfizer INC. | $582.53 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $438.49 | 2019-2022 | |
| Lilly USA, LLC | $423.05 | 2019-2022 | |
| Antares Pharma, INC. | $359.47 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.86 | 2019-2022 | |
| Assertio Therapeutics, INC. | $324.58 | 2019-2020 | |
| Amarin Pharma, INC. | $319.82 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Summe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.